Now showing items 648-667 of 838

    • Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. 

      Orlando, G; Law, PJ; Cornish, AJ; Dobbins, SE; Chubb, D; Broderick, P; Litchfield, K; Hariri, F; Pastinen, T; Osborne, CS; Taipale, J; Houlston, RS (2018-10)
      Efforts are being directed to systematically analyze the non-coding regions of the genome for cancer-driving mutations1-6. cis-regulatory elements (CREs) represent a highly enriched subset of the non-coding regions of the ...
    • Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. 

      Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; Sideris, S; Zafeiriou, Z; Sumanasuriya, S; Smith, AD; Mehra, N; Jayaram, A; Perez-Lopez, R; Mateo, J; Parker, C; Dearnaley, DP; Tunariu, N; Reid, A; Attard, G; de Bono, JS (2016-11)
      BACKGROUND:The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen ...
    • Protein-altering germline mutations implicate novel genes related to lung cancer development. 

      Ji, X; Mukherjee, S; Landi, MT; Bosse, Y; Joubert, P; Zhu, D; Gorlov, I; Xiao, X; Han, Y; Gorlova, O; Hung, RJ; Brhane, Y; Carreras-Torres, R; Christiani, DC; Caporaso, N; Johansson, M; Liu, G; Bojesen, SE; Le Marchand, L; Albanes, D; Bickeböller, H; Aldrich, MC; Bush, WS; Tardon, A; Rennert, G; Chen, C; Byun, J; Dragnev, KH; Field, JK; Kiemeney, LF; Lazarus, P; Zienolddiny, S; Lam, S; Schabath, MB; Andrew, AS; Bertazzi, PA; Pesatori, AC; Diao, N; Su, L; Song, L; Zhang, R; Leighl, N; Johansen, JS; Mellemgaard, A; Saliba, W; Haiman, C; Wilkens, L; Fernandez-Somoano, A; Fernandez-Tardon, G; Heijden, EHFMVD; Kim, JH; Davies, MPA; Marcus, MW; Brunnström, H; Manjer, J; Melander, O; Muller, DC; Overvad, K; Trichopoulou, A; Tumino, R; Goodman, GE; Cox, A; Taylor, F; Woll, P; Wichmann, E; Muley, T; Risch, A; Rosenberger, A; Grankvist, K; Johansson, M; Shepherd, F; Tsao, M-S; Arnold, SM; Haura, EB; Bolca, C; Holcatova, I; Janout, V; Kontic, M; Lissowska, J; Mukeria, A; Ognjanovic, S; Orlowski, TM; Scelo, G; Swiatkowska, B; Zaridze, D; Bakke, P; Skaug, V; Butler, LM; Offit, K; Srinivasan, P; Bandlamudi, C; Hellmann, MD; Solit, DB; Robson, ME; Rudin, CM; Stadler, ZK; Taylor, BS; Berger, MF; Houlston, R; McLaughlin, J; Stevens, V; Nickle, DC; Obeidat, M; Timens, W; Artigas, MS; Shete, S; Brenner, H; Chanock, S; Brennan, P; McKay, JD; Amos, CI (2020-05-11)
      Few germline mutations are known to affect lung cancer risk. We performed analyses of rare variants from 39,146 individuals of European ancestry and investigated gene expression levels in 7,773 samples. We find a large-effect ...
    • Proteomic research in sarcomas - current status and future opportunities. 

      Burns, J; Wilding, CP; L Jones, R; H Huang, P (2020-04)
      Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ...
    • Protracted dormancy of pre-leukemic stem cells. 

      Ford, AM; Mansur, MB; Furness, CL; van Delft, FW; Okamura, J; Suzuki, T; Kobayashi, H; Kaneko, Y; Greaves, M (2015-11)
      Cancer stem cells can escape therapeutic killing by adopting a quiescent or dormant state. The reversibility of this condition provides the potential for later recurrence or relapse, potentially many years later. We describe ...
    • Pten Regulates Epithelial Cytodifferentiation during Prostate Development. 

      Lokody, IB; Francis, JC; Gardiner, JR; Erler, JT; Swain, A (2015-01)
      Gene expression and functional studies have indicated that the molecular programmes involved in prostate development are also active in prostate cancer. PTEN has been implicated in human prostate cancer and is frequently ...
    • Publisher Correction: Cancer genetics, precision prevention and a call to action. 

      Turnbull, C; Sud, A; Houlston, RS (2019-01)
      In the version of this article originally published, there was an error in the second-to-last sentence of the abstract. In this sentence, the final phrase "to identify carriers of first-wave gene mutation carriers" should ...
    • Quantification of subclonal selection in cancer from bulk sequencing data. 

      Williams, MJ; Werner, B; Heide, T; Curtis, C; Barnes, CP; Sottoriva, A; Graham, TA (2018-06)
      Subclonal architectures are prevalent across cancer types. However, the temporal evolutionary dynamics that produce tumor subclones remain unknown. Here we measure clone dynamics in human cancers by using computational ...
    • Quantitative histology analysis of the ovarian tumour microenvironment. 

      Lan, C; Heindl, A; Huang, X; Xi, S; Banerjee, S; Liu, J; Yuan, Y (2015-11-17)
      Concerted efforts in genomic studies examining RNA transcription and DNA methylation patterns have revealed profound insights in prognostic ovarian cancer subtypes. On the other hand, abundant histology slides have been ...
    • Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. 

      Vyse, S; McCarthy, F; Broncel, M; Paul, A; Wong, JP; Bhamra, A; Huang, PH (2018-01)
      Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies to overcome ...
    • RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. 

      Lionarons, DA; Hancock, DC; Rana, S; East, P; Moore, C; Murillo, MM; Carvalho, J; Spencer-Dene, B; Herbert, E; Stamp, G; Damry, D; Calado, DP; Rosewell, I; Fritsch, R; Neubig, RR; Molina-Arcas, M; Downward, J (2019-07)
      RAC1 P29 is the third most commonly mutated codon in human cutaneous melanoma, after BRAF V600 and NRAS Q61. Here, we study the role of RAC1P29S in melanoma development and reveal that RAC1P29S activates PAK, AKT, and a ...
    • Radiation Safety Culture in the UK Medical Sector: A Top to Bottom Strategy. 

      Chapple, C-L; Bradley, A; Murray, M; Orr, P; Reay, J; Riley, P; Rogers, A; Sandhu, N; Thurston, J (2017-04)
      UK professional bodies have established a number of sectorial working parties to provide guidance on the improvement of radiation safety (RS) culture in the workplace. The medical sector provides unique challenges in this ...
    • Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. 

      Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; Warmuth-Metz, M; Sánchez Aliaga, E; Calmon, R; Hargrave, DR; Cañete, A; Massimino, M; Azizi, AA; Le Deley, M-C; Saran, F; Rousseau, RF; Zahlmann, G; Garcia, J; Vassal, G; Grill, J; Morgan, PS; Jaspan, T (2020-01-10)
      BACKGROUND:The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/Temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ...
    • A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. 

      Glasspool, RM; Brown, R; Gore, ME; Rustin, GJS; McNeish, IA; Wilson, RH; Pledge, S; Paul, J; Mackean, M; Hall, GD; Gabra, H; Halford, SER; Walker, J; Appleton, K; Ullah, R; Kaye, S; Scottish Gynaecological Trials Group (2014-04)
      BACKGROUND:Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis ...
    • Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. 

      Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; Holcombe, C; Boileau, JF; Provencher, L; Robidoux, A; Rimawi, M; McIntosh, SA; Shalaby, I; Stein, RC; Thirlwell, M; Dolling, D; Morden, J; Snowdon, C; Perry, S; Cornman, C; Batten, LM; Jeffs, LK; Dodson, A; Martins, V; Modi, A; Osborne, CK; Pogue-Geile, KL; Cheang, MCU; Wolmark, N; Julian, TB; Fisher, K; MacKenzie, M; Wilcox, M; Huang Bartlett, C; Koehler, M; Dowsett, M; Bliss, JM; Jacobs, SA (2019-01)
      PURPOSE:CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ...
    • Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. 

      Kühnl, A; Cunningham, D; Hutka, M; Peckitt, C; Rozati, H; Morano, F; Chong, I; Gillbanks, A; Wotherspoon, A; Harris, M; Murray, T; Chau, I (2018-01)
      In patients presenting with peripheral lymphadenopathy, it is critical to effectively identify those with underlying cancer who require urgent specialist care.We analyzed a large dataset of 1000 consecutive patients with ...
    • Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. 

      Chubb, D; Broderick, P; Dobbins, SE; Frampton, M; Kinnersley, B; Penegar, S; Price, A; Ma, YP; Sherborne, AL; Palles, C; Timofeeva, MN; Bishop, DT; Dunlop, MG; Tomlinson, I; Houlston, RS (2016-06-22)
      Colorectal cancer (CRC) displays a complex pattern of inheritance. It is postulated that much of the missing heritability of CRC is enshrined in high-impact rare alleles, which are mechanistically and clinically important. ...
    • Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. 

      Litchfield, K; Levy, M; Dudakia, D; Proszek, P; Shipley, C; Basten, S; Rapley, E; Bishop, DT; Reid, A; Huddart, R; Broderick, P; Castro, DGD; O'Connor, S; Giles, RH; Houlston, RS; Turnbull, C (2016-12-20)
      Testicular germ cell tumour (TGCT) is the most common cancer in young men. Here we sought to identify risk factors for TGCT by performing whole-exome sequencing on 328 TGCT cases from 153 families, 634 sporadic TGCT cases ...
    • Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. 

      Harrison, PT; Vyse, S; Huang, PH (2020-04)
      Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation) ...